WO2010147268A1 - 자궁경부암 백신 - Google Patents
자궁경부암 백신 Download PDFInfo
- Publication number
- WO2010147268A1 WO2010147268A1 PCT/KR2009/006062 KR2009006062W WO2010147268A1 WO 2010147268 A1 WO2010147268 A1 WO 2010147268A1 KR 2009006062 W KR2009006062 W KR 2009006062W WO 2010147268 A1 WO2010147268 A1 WO 2010147268A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hpv
- type
- vlp
- virus
- protein
- Prior art date
Links
- 206010008342 Cervix carcinoma Diseases 0.000 title claims abstract description 17
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title claims abstract description 17
- 201000010881 cervical cancer Diseases 0.000 title claims abstract description 17
- 229960005486 vaccine Drugs 0.000 title abstract description 27
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 212
- 238000000034 method Methods 0.000 claims abstract description 81
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 26
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 26
- 239000002245 particle Substances 0.000 claims abstract description 17
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 108
- 239000011780 sodium chloride Substances 0.000 claims description 54
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 50
- 229960002897 heparin Drugs 0.000 claims description 50
- 229920000669 heparin Polymers 0.000 claims description 50
- 239000002671 adjuvant Substances 0.000 claims description 44
- 238000004587 chromatography analysis Methods 0.000 claims description 44
- 239000012535 impurity Substances 0.000 claims description 42
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 39
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 39
- 238000005277 cation exchange chromatography Methods 0.000 claims description 36
- 229940032077 cervical cancer vaccine Drugs 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 17
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 17
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 239000001166 ammonium sulphate Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 239000006166 lysate Substances 0.000 claims description 7
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 6
- 230000009089 cytolysis Effects 0.000 claims description 5
- 238000012870 ammonium sulfate precipitation Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910021480 group 4 element Inorganic materials 0.000 claims description 2
- 229910052735 hafnium Inorganic materials 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 229910021481 rutherfordium Inorganic materials 0.000 claims description 2
- 229910052712 strontium Inorganic materials 0.000 claims description 2
- 229910052726 zirconium Inorganic materials 0.000 claims description 2
- 230000028993 immune response Effects 0.000 abstract description 25
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- 230000036039 immunity Effects 0.000 abstract description 7
- 230000007969 cellular immunity Effects 0.000 abstract description 6
- 230000004727 humoral immunity Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 91
- 102000004169 proteins and genes Human genes 0.000 description 90
- 239000002158 endotoxin Substances 0.000 description 56
- 229920006008 lipopolysaccharide Polymers 0.000 description 56
- 238000000746 purification Methods 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 229940037003 alum Drugs 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- -1 Ba (OH) 2 Chemical compound 0.000 description 16
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 16
- 101000641175 Human papillomavirus type 18 Major capsid protein L1 Proteins 0.000 description 15
- 230000001988 toxicity Effects 0.000 description 15
- 231100000419 toxicity Toxicity 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 239000011347 resin Substances 0.000 description 13
- 229920005989 resin Polymers 0.000 description 13
- 229940124957 Cervarix Drugs 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000012148 binding buffer Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 229940124897 Gardasil Drugs 0.000 description 10
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000003472 neutralizing effect Effects 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
- 229920000053 polysorbate 80 Polymers 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 229930182830 galactose Natural products 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 101100209954 Human papillomavirus type 16 L1 gene Proteins 0.000 description 7
- 102000008070 Interferon-gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 229960003130 interferon gamma Drugs 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000020176 deacylation Effects 0.000 description 5
- 238000005947 deacylation reaction Methods 0.000 description 5
- 230000001571 immunoadjuvant effect Effects 0.000 description 5
- 239000000568 immunological adjuvant Substances 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002736 nonionic surfactant Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108020000946 Bacterial DNA Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 101000641177 Human papillomavirus type 16 Major capsid protein L1 Proteins 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 241001112090 Pseudovirus Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011210 chromatographic step Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000004676 glycans Polymers 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 description 2
- 101150075239 L1 gene Proteins 0.000 description 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 2
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- CPRMKOQKXYSDML-UHFFFAOYSA-M rubidium hydroxide Chemical compound [OH-].[Rb+] CPRMKOQKXYSDML-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101150038242 GAL10 gene Proteins 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000341657 Human papillomavirus type 18 Species 0.000 description 1
- 241000883306 Huso huso Species 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000235088 Saccharomyces sp. Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- ZJRXSAYFZMGQFP-UHFFFAOYSA-N barium peroxide Chemical compound [Ba+2].[O-][O-] ZJRXSAYFZMGQFP-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- QUWFSKKBMDKAHK-SBOJBMMISA-A chembl2103793 Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 QUWFSKKBMDKAHK-SBOJBMMISA-A 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- VLWBTHYKMPSZNK-UHFFFAOYSA-L disodium hydrogen phosphate hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O VLWBTHYKMPSZNK-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- PWRJGELXVCNTCM-UHFFFAOYSA-L magnesium;carbonate;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[O-]C([O-])=O PWRJGELXVCNTCM-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 125000004964 sulfoalkyl group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to a human cervical cancer vaccine pharmaceutical composition, a method for preventing human cervical cancer, and a method for preparing human papilloma virus (HPV) L1 virus-like particles (VLP).
- HPV human papilloma virus
- VLP L1 virus-like particles
- HPVs human Papillomaviruses
- HPV types 16 and 18 the incidence of cancer among women infected with HPV, especially HPV types 16 and 18, is 500 times higher than that of non-infected people, and they are known to have malignant transformation to cervical cancer after infection through genital epithelial cells.
- VLP HPV virus-like particles
- L1 protein L1 protein, about 55 kDa
- genotype-specific Type-specific has the advantage that can be expected high efficiency as a vaccine candidate.
- Gadsil is a vaccine developed using "Alum,” an adjuvant commonly used for each of the four most common HPV types 6, 11, 16 and 18 antigens.
- GlaxoSmithKline's The Seribex is a vaccine developed using AS04, an adjuvant developed exclusively for HPV types 16 and 18, the most common cervical cancer-causing factors.
- Alum an adjuvant used in Gadacil
- diphtheria, tetanus and hepatitis B vaccines which has been reported to increase antigen stability and induce release of cytokines.
- cytokines There is a big disadvantage that its use is limited as it is ineffective against all antigens and promotes only humoral immune responses.
- MPL monophosphoryl lipid A
- bacterial DNA is known to activate various immune cells without significant side effects, especially as an adjuvant (McCluskie MJ, etal ..CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.JImmunol. Nov 1; 161 (9): 4463-6.1998).
- Yamamoto et al. In Japan claimed that CG-containing sequences played an important role and were widely known by Krieg et al. (Yamamoto S. et al. Unique palindromic sequences in synthetic oligonucleotides are required to .. induce IFN and augment IFN- mediated natural killer activity J.Immunol 148: 4072,1992; Krieg AM, Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides Curr Oncol Rep Mar; 6 (2)....: 88-95.2004).
- CPG's research confirmed the possibility of synthetic DNA (CpG-ODN) containing unmethylated CG as a result of DNA anticancer drugs. S substitution and the like have been studied. This effort has enabled CpG-ODN-related products to be clinically tested as an adjuvant as well as as an anticancer agent (http://www.coleypharma.com).
- CPG 7909 is a phosphorothioate oligonucleotide that induces anti-DNA Abs (Clin Immunol. 2001 Aug; 100 (2): 157-63), which is an autoimmune disease such as systemic lupus erythematosus (SLE). (J Clin Immunol. 1986 July; 6 (4): 292-8). It is also known that phosphorothioate structure acts as TI Ag and confounds immune defense against infection (Mol Immunol. 1998 Dec; 35 (18): 1161-70).
- LPS which has been known for its anticancer effects since the 1950s, has been difficult to use due to its toxicity which can cause death by pulmonary disease even with ng contamination.
- MPL monophosphoryl lipid A
- the present inventors have tried to develop a novel vaccine that can solve the problems of the conventional cervical cancer vaccine described above.
- the present inventors found that the non-toxic LOS (Lipopolysaccharide) from which some fatty acids were removed from lipid A as an adjuvant in the immunization process using the L1 VLP of HPV 16 or 18 was significantly larger than that of the conventional VLP-based vaccine.
- the present invention has been completed.
- Another object of the present invention to provide a method for preventing human cervical cancer.
- Another object of the present invention is to provide a novel nucleic acid sequence encoding the L1 VLP of HPV 16.
- Another object of the present invention is to provide a novel nucleic acid sequence encoding the L1 VLP of HPV 18.
- Still another object of the present invention is to provide a Saccharomyces cerevisiae transformed with the novel nucleic acid sequence.
- the present invention provides a kit comprising: (a) L1 virus-like particle (VLP) of human papilloma virus (HPV) type 16, L1 VLP of HPV type 18, or a combination thereof; And (ii) deacylated nontoxic Lipooligosaccharides (LOS); And (b) a human cervical cancer vaccine pharmaceutical composition comprising a pharmaceutically acceptable carrier.
- VLP virus-like particle
- HPV human papilloma virus
- LOS deacylated nontoxic Lipooligosaccharides
- a human cervical cancer vaccine pharmaceutical composition comprising a pharmaceutically acceptable carrier.
- the present invention provides a method for preventing human cervical cancer comprising administering the pharmaceutical composition of the present invention to a human.
- the present inventors have tried to develop a novel vaccine that can solve the problems of the conventional cervical cancer vaccine described above.
- the present inventors have found that the use of deacylated nontoxic LOS (Lipooligosaccharide) as an adjuvant in the immunization process using the L1 VLP of HPV 16 or 18 as an adjuvant results in a significantly improved HPV immune response than the conventional VLP-based vaccine. Induction was confirmed to be an excellent vaccine for the prevention of cervical cancer.
- LOS Lipooligosaccharide
- the VLPs used in the pharmaceutical compositions of the present invention are derived from HPV type 16 L1 or HPV type 18 L1.
- HPV type 16 or HPV type 18 is known as high risk HPV and is representative of HPV causing cervical cancer.
- HVP L1 protein refers to a major protein constituting the capsid of HPV as expressed from the L1 gene of HPV.
- the L1 protein has the property of self-assembling into virus like particles (VLPs) under suitable conditions with L2 protein, which is another minor protein constituting the capsid, or with L1 protein alone.
- VLPs virus like particles
- VLPs used in the present invention include the naturally occurring total sequence of the L1 protein of HPV type 16 or HPV type 18 and functional L1 protein derivatives thereof.
- HPV L1 functional derivative refers to a derivative of a naturally-derived HPV L1 protein that is not identical to the naturally-derived HPV L1 total sequence but can form a VLP and induce an immune response.
- the L1 functional derivative is a truncated L1 protein from which a nuclear localization signal has been removed, eg, in the case of HPV type 16 L1, the form of the C-terminal 34 amino acids removed, of HPV type 18 L1 In this case, the C-terminal 35 amino acid removed form is an HPV L1 functional derivative that can be used in the present invention
- the exemplary amino acid sequences of the L1 VLPs of HPV 16 and 18 used in the present invention are shown in SEQ ID NO: 2, respectively. And the fourth sequence.
- HPV 16 L1 VLP or HPV 18 L1 VLP is used, preferably both HPV 16 L1 VLP and HPV 18 L1 VLP.
- HPV Type 31 HPV Type 45, HPV Type 6a, HPV Type 6b, HPV Type 11, HPV Type 33, HPV Type 35, HPV Type 39, HPV And at least one L1 VLP selected from the group consisting of L1 VLPs of type 51, HPV type 52, HPV type 56, HPV type 58, and HPV type 68.
- the L1 VLPs used in the present invention may be fused with other proteins such as L2 proteins.
- the biggest feature of the vaccine composition of the present invention is the use of deacylated nontoxic LOS (Lipooligosaccharide) as an adjuvant.
- LOS Longitigosaccharide
- LPS lipopolysaccharide
- the LOS prior to deacylation preferably has a molecular weight of 5,000-10,000 Da.
- deacylated LOS refers to the removal of fatty acids bound to the glucosamine of lipid A by -C (O) O- bond in this LOS, resulting in a significant reduction in toxicity compared to LPO.
- the deacylated LOS of the present invention is bound to -C (O) O- bonds by deacylation of lipid A. Indicates that it was removed.
- Deacylated non-toxic LOS can be prepared through a variety of methods, but Korean Patent Registration No. 0456681, which is the prior patent of the present inventors; WO 2004/039413; Korean Patent Registration No. 0740237; And the methods disclosed in WO 2006/121232.
- LPS is treated with a strong base (eg, 2N NaOH) to deacylate to remove some fatty acids from lipid A to detoxify.
- a strong base eg, 2N NaOH
- the deacylated non-toxic LOS used as an adjuvant in the present invention is detoxylated by an alkali treatment to LPS.
- the alkali include NaOH, KOH, Ba (OH) 2 , CsOH, Sr (OH) 2 , Ca (OH) 2 , LiOH, RbOH, Mg (OH) 2 , and more preferably NaOH, KOH , Ba (OH) 2 , Ca (OH) 2 , LiOH and Mg (OH) 2 , even more preferably NaOH, KOH and Mg (OH) 2 , most preferably NaOH.
- the degree of toxicity of LPS can be analyzed through various methods known in the art. For example, toxicity may be analyzed by measuring the amount of tumor necrosis factor- ⁇ secreted in LPS-treated THP-1 (Acute monocytic leukemia).
- the deacylated nontoxic LOS of the present invention induces relatively low amounts of TNF- ⁇ secretion compared to conventional LPS.
- the molecular weight is generally small compared to conventionally used LPS.
- the deacylated non-toxic LOS used in the present invention is 1,500-10,000 Da, more preferably 2,000-5,000 Da, even more preferably 2,000-4,000 Da, even more preferably 3,000-4,000 Da, Most preferably, it has a molecular weight of 3,200-3,7000 Da.
- Such molecular weight can be measured using conventional methods in the art, for example MALDI-MASS.
- the adjuvant deacylated non-toxic LOS of the present invention is derived from E. coli , and most preferably from E. coli EG0021 (KCCM 10374), which is our own bacterium. It is.
- the deacylated non-toxic LOS used in the present invention is not only excellent in immunostimulatory efficacy compared to conventional adjuvant but also much reduced in toxicity, which is very suitable for the vaccine composition of the present invention.
- the deacylation ratio of the present invention is higher than that of monophosphoryl lipid A (MPL) obtained through phosphorylation of leaf A obtained by removing the polysaccharide chain of LPS to remove the toxicity of LPS.
- Toxicity LOS is much less toxic.
- the vaccine composition of the present invention can exert sufficient immune response with its basic composition, namely HPV 16 L1 VLP, HPV 18 L1 VLP, or a combination thereof and deacylated non-toxic LOS to exert cervical cancer prevention efficacy.
- the vaccine composition of the present invention may further comprise other adjuvant, for example with Group 2 elements selected from the group consisting of Mg, Ca, Sr, Ba and Ra, Ti, Zr, Hf and Rf. Salts of Group 4 elements or aluminum selected from the group consisting of or hydrates thereof.
- the salts are preferably formed with oxides, peroxides, hydroxides, carbonates, phosphates, pyrophosphates, hydrogenphosphates, dihydrogenphosphates, sulfates or silicates.
- an adjuvant that may additionally be used in the vaccine composition of the present invention is magnesium hydroxide, magnesium carbonate hydroxide pentahydrate, titadium didoxide, calcium carbonate, barium oxide, barium hydroxide, Barium peroxide, barium sulfate, calcium sulfate, calcium pyrophosphate, magnesium carbonate, magnesium oxide, aluminum hydroxide, aluminum phosphate and hydrated aluminum potassium sulfate (Alum).
- the adjuvant which may additionally be used in the vaccine composition of the present invention is aluminum hydroxide.
- the L1 VLP of HPV type 16 or 18 comprises the steps of: (i) culturing a yeast comprising the L1-coding nucleotide sequence of HPV type 16 or 18; (Ii) lysis of the cultured yeast; (Iii) conducting ammonium sulphate precipitation on the yeast lysate to remove impurities; (Iii) Heparin chromatography or cation-exchange chromatography is performed on the resultant from which the impurities have been removed.
- Pharmaceutically acceptable carriers included in the vaccine pharmaceutical composition of the present invention are conventionally used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin , Calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. It is not limited.
- the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
- a lubricant e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, a kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mann
- the pharmaceutical composition of the present invention may be administered orally or parenterally, preferably parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, or the like. have.
- Suitable dosages of the pharmaceutical compositions of the present invention may vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to response of the patient. Can be.
- the oral dosage of the pharmaceutical composition of the present invention is preferably 0.0001-1000 mg / kg (body weight) per day.
- compositions of the present invention may be prepared in unit dose form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporating into a multi-dose container.
- the formulation may be in the form of a solution, suspension or emulsion in an oil or an aqueous medium, or may be in the form of extracts, powders, granules, tablets or capsules, and may further include a dispersant or stabilizer.
- the cervical cancer vaccine composition of the present invention induces a greater immune response to HPV than the conventional cervical cancer vaccines Cervarix TM and Gardasil TM , and thus is more effective in preventing cervical cancer as well as the deacylated non-toxic LOS used as an adjuvant. It has very little toxicity and is very good in terms of safety.
- cervical cancer vaccine compositions of the present invention as demonstrated in the following examples, levels of interferon- ⁇ , IgG2a and IgG2b associated with Th1 type immune response (cellular immunity) when the vaccine composition of the present invention is administered It is higher than Cervarix TM and Gardasil TM , and also has higher IgG1 levels related to Th2 type immune response (humoral immunity) than Cervarix TM and Gardasil TM .
- the cervical cancer vaccine composition of the present invention is superior to Cervarix TM and Gardasil TM in both Th1 type immune response (cellular immunity) and Th2 type immune response (humidity immunity) in immunity against HPV.
- the invention provides a method for preparing human papilloma virus (HPV) L1 virus-like particles (VLPs) comprising the following steps:
- the present inventors studied to develop a purification method that can simplify the production process of HPV VLPs and increase the yield in the production process using the yeast expression system of HPV VLPs for vaccine production against HPV.
- the yeast cell lysate is precipitated by ammonium sulfate and subjected to heparin chromatography or cation-exchange chromatography, the purification efficiency (yield and purity) is greatly increased. It was confirmed that it could be improved.
- HPV from which the L1 protein is derived in the method of the present invention is not particularly limited, and HPV type 6a, HPV type 6b, HPV type 11, HPV type 16, HPV type 18, HPV type 31, HPV type 33, HPV Type 35, HPV Type 39, HPV Type 45, HPV Type 51, HPV Type 52, HPV Type 56, HPV Type 58, and HPV Type 68.
- the L1 protein of the present invention is derived from HPV selected from the group consisting of HPV type 6a, HPV type 6b, HPV type 11, HPV type 16, HPV type 18, HPV type 31, HPV type 33 and HPV type 45 More preferably from HPV type 16 and type 18.
- Cells used as host cells in the present invention is yeast, for example, baker's yeast, Saccharomyces cerevisiae , Saccharomyces pastorianus ), Saccharomyces sp., Schizosaccharomyces pombe , etc. may be used, but is not limited thereto. Most preferably the host yeast of the present invention is Saccharomyces cerevisiae .
- Transformed yeast expressing HPV L1 protein refers to yeast cells transformed with an expression vector that successfully expresses HPV L1 protein.
- Various promoters known in the art upstream of the HPV L1 gene to be expressed in the expression vector such as the GALl promoter, the GALl0 promoter (Johnson, M., and Davies, RW, Mol. And Cell. Biol., 4: 1440- 1448 (1984)), ADH2 promoter (Russell, D., et al., J. Biol. Chem., 258: 2674-2682, (1983)), PH05 (EMBO J. 6: 675-680, (1982) )), PH05 promoter (EMBO J.
- MFal promoter may be linked, and polyadenylation sequences such as ADHI, MFal or TPI derived polyA sequences (Alber, T. and Kawasaki) , G., J. Mol. & Appl. Genet. 1: 419-434 (1982).
- YEp6, YEpl3, YEp4, and YEG ⁇ SN Kim, et al., J. Virol. Methods 139 (2007) 24-30; R. Kirnbauer, et al., J Virol 67 (1993) 6929-6936 as yeast expression vectors Is known.
- HPV L1 protein expression transformed yeast can be readily prepared using methods known in the art, such methods being described in US Pat. Nos. US 7250170, US 6613557, US 5888516, US 5871998, US 5618536, US5437951 and the like, the contents of these patent documents are incorporated herein by reference.
- the transforming yeast is cultured in a medium to which at least one carbon source of glucose and galactose is added as a carbon source.
- the weight ratio of glucose and galactose contained in the medium is in the above range, the expression of HPV L1 protein is maximized.
- Exemplary media used in the culture of the transformed yeast are YPDG media (including yeast extract, peptone, glucose and galactose).
- the method for lysing yeast cells cultured in the present invention may be a method capable of obtaining a total lysate of yeast cells, and is not limited to a specific method.
- Dissolution methods that can be used in the present invention include, for example, a method using crushing by sonication, glass beads, but is not limited thereto.
- Ammonium sulfate was added to the yeast lysates to precipitate the expressed protein and remove impurities.
- the concentration of ammonium sulphate added is 20-60% by weight, more preferably 40-50% by weight, most preferably 42-48% by weight. If the concentration of ammonium sulfate is less than 40% by weight, the precipitation efficiency of the HPV L1 protein expressed in the present invention is lowered, and if it is more than 50% by weight, the effect of increasing the L1 protein precipitation by the increase of ammonium sulfate cannot be obtained.
- protein pellets formed by ammonium sulphate precipitation are dissolved and incubated at 4 ° C. for at least 12 hours with addition of at least 0.5 M NaCl.
- step (iii) The solution obtained in step (iii) is exchanged by dialysis in a buffer containing a low concentration of salt (eg, NaCl) (eg, phosphate buffer), and then incubated at room temperature to remove impurities by making them insoluble.
- a buffer containing a low concentration of salt eg, NaCl
- phosphate buffer eg, phosphate buffer
- the concentration of the low concentration salt is 0.001-0.3 M, more preferably 0.01-0.2 M, most preferably 0.1-0.8 M and the salt used is NaCl, KCl, MgCl 2 , CaCl 2 , Na 2 SO 4 and (NH 4 ) 2 SO 4 , most preferably NaCl.
- the low concentration salt treatment process is carried out in the presence of a nonionic surfactant, the nonionic surfactant being for example polyoxyalkylene sorbitan fatty acid esters, sorbitan fatty acid esters, alkylene Glycol fatty acid esters, polyoxyalkylene fatty acid esters, fatty acid esters, polyoxyalkylene fatty acid ethers, C 16-24 fatty acids, fatty acid mono-, di- or poly-glycerides, polyoxyalkylene alkyl phenols, alkyl phenyl ethers, poly Oxyethylene polyoxypropylene block copolymers, fatty amine oxides, fatty acid alkanolamides, alkyl celluloses, carboxyalkyl cellulose or polyoxyalkylene castor oil derivatives, preferably polyoxyethylene (20) sorbitan monolau Rate (twin 20), polyoxyethylene (4) sorbitan monolaurate (twin 21), polyoxyethylene (20)
- the treatment of this low concentration of NaCl is very efficient for removing impurities and is a step that greatly contributes to shortening the process and improving the purification efficiency in the method of the present invention.
- this step shows the effect of greatly increasing the purification efficiency by removing impurities in a simple way.
- Heparin chromatography or cation exchange chromatography are performed on the solution from which impurities are removed.
- the heparin resin is first equilibrated with a suitable binding buffer before applying the result of step (iii) or (iii-2) to the heparin resin column.
- the binding buffer preferably comprises NaCl and a nonionic surfactant (eg, Tweeen 80), with NaCl being preferably low in concentration (0.1-0.2 M).
- the sample is then subjected to heparin chromatography and the protein bound to the resin is eluted.
- the elution method is preferably a NaCl linear gradient, more preferably eluting impurities in a 0.33-0.66 M NaCl linear gradient, and then eluting the desired L1 protein at a 0.66-2 M NaCl linear gradient.
- Cation exchange chromatography can be carried out using a variety of resins, preferably using a cation exchanger combined with sulfo, sulfoalkyl (e.g. sulfomethyl, sulfoethyl and sulfopropyl), phosphate or phosphatealkyl functional groups. And most preferably, using a cation exchanger having a phosphate functional group bonded thereto.
- the heparin resin is first equilibrated with a suitable binding buffer before applying the result of step (iii) or (iii-2) to the heparin resin column.
- the binding buffer preferably comprises NaCl and a nonionic surfactant (eg, Tweeen 80), with NaCl being preferably low in concentration (0.3-0.4 M).
- a nonionic surfactant eg, Tweeen 80
- the sample is then subjected to cation exchange chromatography and the protein bound to the resin is eluted.
- the elution method is preferably NaCl step concentration gradient, more preferably eluting the desired L1 protein using an elution buffer containing 0.6 M, 0.7 M, 0.8 M and 1 M NaCl.
- the L1 protein fraction obtained through the chromatography process is concentrated by a membrane filter.
- the chromatography fractions are concentrated using a membrane capable of cut-off a molecular weight of 50-100 kDa.
- VLPs with an average size of about 50 nm have a larger size than other proteins and are concentrated through the membrane, while most residual impurities are removed through the membrane. This step thus increases the purity of the HPV 16 L1 and at the same time increases the concentration.
- the method of the present invention maximizes the purification efficiency of the L1 protein by using a method of removing impurities by treating the cell lysate with specific conditions before the chromatography step.
- the cell lysate is first precipitated by adding ammonium sulphate and secondly incubated in low salt condition to remove impurities.
- the impurities are removed by incubation under low salt condition after ammonium sulfate precipitation, 80% of the impurities can be removed, and L1 protein can recover more than 80%, thereby increasing the purity by a simple method. Therefore, high purity L1 protein can be purified without multiple chromatographic steps and applied to production and purification on a pilot and industrial scale, which can greatly reduce the time, manufacturing cost and labor required for protein production. have.
- the invention provides nucleic acid sequences of L1 virus-like particles (VLPs) of human papilloma virus (HPV) type 16 comprising the nucleotide sequence of SEQ ID NO: 1.
- the present invention also provides a nucleic acid sequence of L1 virus-like particle (VLP) of human papilloma virus (HPV) type 18 comprising the nucleotide sequence of SEQ ID NO: 3.
- the invention is Saccharomyces cerevisiae transformed with the nucleic acid sequence of the L1 virus-like particle (VLP) of the Roman virus (HPV) type 16 (Accession Number: KCCM11036P) To provide.
- the present invention also provides Saccharomyces cerevisiae (Accession Number: KCCM11037P) transformed with the nucleic acid sequence of the human papilloma virus (HPV) type 18 L1 virus-like particle (VLP).
- the nucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 3 are optimized for high efficiency expression of L1 protein-encoding nucleic acid sequences of HPV.
- the cervical cancer vaccine composition of the present invention uses HPV 16 L1 VLP, HPV 18 L1 VLP or HPV 16 L1 VLP and HPV 18 L1 VLP as antigen and deacylated nontoxic LOS as an adjuvant.
- deacylated non-toxic LOS induces a synergistic immune response to HPV by increasing both Th1-type immune responses (cellular immunity) and Th2-type immune responses in the immune response induced by HPV L1 VLPs. .
- the cervical cancer vaccine composition of the present invention is superior to Cervarix TM and Gardasil TM in both Th1 type immune response (cellular immunity) and Th2 type immune response (humoral immunity) in immunity against HPV, thus cervical cancer vaccine It exhibits excellent efficacy as.
- the method for producing HPV L1 VLP of the present invention can obtain high purity L1 protein even after one chromatographic step, and when applied to production and purification on a pilot and industrial scale, the time required for protein production, There is an effect that can greatly reduce the manufacturing cost and labor.
- 1 and 2 are genetic maps for yeast expression vectors (YEGs) expressing HPV type 16 and 18 L1 VLP proteins.
- AmpR is an ampicillin resistance gene
- AmpR is an ampicillin resistance gene
- Ura3 is an orotidine 5-phosphate decarboxylase synthetic gene
- 2-micron is the origin of replication, and the remaining symbols indicate restriction enzyme positions.
- FIG. 3 is a schematic view of the purification process of HPV 16 L1 and HPV 18 L1. After ammonium sulphate precipitation, samples were removed from the protein insoluble at low concentrations of NaCl.
- heparin chromatography (method 1) or cation-exchange chromatography (method 2) was used.
- FIG. 4 and 6 are the results of purification of HPV 16 L1.
- Figure 4 is a SDS-PAGE results after the heparin chromatography proceeds without removing the insoluble impurities.
- FIG. 5 shows SDS-PAGE results of heparin chromatography in Method 1 of FIG. 1C.
- FIG. 6 shows Western blotting results of primary heparin chromatography. Lanes 1 and 2 are loaded and unbound samples and lanes 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 are fractions 9, 12, 15 and 18, respectively. , 21, 24, 27, 30, 33, 36, 39, 42, 45 and 48. Arrows indicate the molecular weight of the L1 protein.
- FIG. 7 and 8 show the results of purification of HPV 16 L1.
- FIG. 7 shows SDS-PAGE results of cation-exchange chromatography in method 2 of FIG. 1C.
- 8 is the result of Western blotting of cation-exchange chromatography.
- Lanes 1 and 2 are loaded and unbound samples and lane 3 represents wash.
- Lanes 4, 5, 6, 7, 8, 9 represent fractions 1, 2, 3, 4, 5, 6.
- Fractions 1, 2, and 3 were eluted with buffers containing 0.6, 0.7, and 0.8 M NaCl, respectively, and fractions 4, 5, and 6 were eluted with buffers containing 1 M NaCl.
- Arrows indicate the molecular weight of the L1 protein.
- FIG. 9 shows the concentration of the L1 fraction of heparin chromatography and cation-exchange chromatography as a result of purification of HPV 16 L1, and was then concentrated using a membrane filter capable of cutting off 50-100 kDa.
- Panel A is the SDS-PAGE result and B is the Western blotting result.
- Lanes 1, 2 and 3 represent HPV 16 L1 purified by BSA, Method 1, and HPV 16 L1 purified by Method 2, respectively. Each sample was quantified by bradford assay and loaded in equal amounts of 200 ng.
- FIG. 10 and 11 are electron micrographs of HPV 16 L1 protein purified by Method 1 and Method 2 of FIG. 1C, respectively.
- Purified HPV 16 L1 protein was adsorbed onto a carbon-coated copper grid, stained with phosphotungstic acid and examined by transmission electron microscopy. The magnification is 41,000 X and the bar represents 100 nm.
- FIG. 12 is the SDS-PAGE result after the heparin chromatography without the process of removing insoluble impurities.
- FIG. 13 is an SDS-PAGE result of heparin chromatography in Method 1 of FIG. 3.
- 14 is a Western blotting result of heparin chromatography. Lanes 1 and 2 are loaded and unbound samples and lanes 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 are fractions 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45 and 48 are represented. Arrows indicate the molecular weight of the L1 protein.
- FIG. 15 and 16 show the results of purification of HPV 18 L1.
- FIG. 15 shows the SDS-PAGE results of cation-exchange chromatography in method 2 of FIG. 1C.
- 16 is the result of western blotting of cation-exchange chromatography.
- Lanes 1 and 2 are loaded and unbound samples and lane 3 represents wash.
- Lanes 4, 5, 6, 7, 8, 9 represent fractions 1, 2, 3, 4, 5, 6.
- Fractions 1, 2, and 3 were eluted with buffers containing 0.6, 0.7, and 0.8 M NaCl, respectively, and fractions 4, 5, and 6 were eluted with buffers containing 1 M NaCl.
- Arrows indicate the molecular weight of the L1 protein.
- FIG. 17 shows the concentration of the L1 fraction of heparin chromatography and cation-exchange chromatography as a result of purification of HPV 18 L1, followed by concentration using a membrane filter capable of cutting off 50-100 kDa.
- Panel A is the SDS-PAGE result and panel B is the Western blotting result.
- Lanes 1, 2 and 3 represent HPV 18 L1 purified by BSA, Method 1, and HPV 18 L1 purified by Method 2, respectively. Each sample was quantified by bradford assay and loaded in equal amounts of 200 ng.
- HPV 18 and 19 are electron micrographs of HPV 18 L1 protein purified by Method 1 and Method 2 of FIG. 1C, respectively. Purified HPV 18 L1 protein was adsorbed onto a carbon-coated copper grid, stained with phosphotungstic acid and examined by transmission electron microscopy. The magnification is 41,000 X and the bar represents 100 nm.
- CIA05 new adjuvant
- TNF- ⁇ secretion cytotoxicity
- FIG. 23 and 24 are graphs showing antibody titers (FIG. 23) and multiples of antibody titer changes (FIG. 24) according to the concentration-specific mixing of the novel immune adjuvant CIA05, HPV 16 L1 VLP, and aluminum hydroxide (Alum). to be. Empty bars are for total IgG, diagonal bars for IgG1 and filled bars for IgG2a.
- FIG. 25 shows the results of analyzing the interferon- ⁇ secretion from splenocytes according to the concentration-specific mixing of the novel immune adjuvant CIA05, HPV 16 L1 VLP, and aluminum hydroxide (Alum).
- the bar of diagonal lines corresponds to a 2 day HPV 16 L1 VLP treatment period and a filled bar 3 days.
- FIG. 26 and FIG. 27 show the results of analysis of serum total IgG titers according to the concentration-specific mixing of the novel immune adjuvant CIA05, HPV 16/18 L1 VLP, and aluminum hydroxide (Alum).
- FIG. 13A shows HPV 16 L1 VLP and
- FIG. 13B shows the results of analyzing total IgG titers for HPV 18 L1 VLPs.
- FIG. 14A serum IgG1 titers
- FIG. 14B shows serum IgG2a titers for HPV 16 L1 VLPs according to the concentration-specific mixing of the new immune adjuvant CIA05, HPV 16/18 L1 VLP and aluminum hydroxide (Alum) It is the result of analyzing (FIG. 14B).
- Codon / expression optimization in yeast Saccharomyces cerevisiae ) of L1 DNA sequences of HPV types 16 and 18 was performed to determine the HPV type 16 L1 DNA sequence of SEQ ID NO: 1 and the HPV type 18 L1 DNA sequence of SEQ ID NO: 3 DNA was synthesized using the “Synthesis in BHB Standard Vectors” service (www.blueheronbio.com), respectively (see SEQ ID NO: 1 and 3).
- Hind III (AAGCTT) and Cla I (ATCGAT) restriction enzyme positions were linked before and after the optimized DNA sequence.
- recombinant plasmid DNA capable of expressing recombinant HPV16L1 and HPV18L1 proteins to be used in the present invention was constructed using a yeast expression vector (YEG) to obtain YEG ⁇ -HPV16L1-ORS and YEG ⁇ -HPV18L1-ORS (FIG. One).
- the cloning process is as follows: a pUCminusMCS vector (Invitrogen) and a yeast expression vector YEG-MCS vector inserted with the HPV type 16 L1 DNA sequence of SEQ ID NO: 1 or the HPV type 18 L1 DNA sequence of SEQ ID NO: 3 Cleavage was performed with Hind III and Cla I.
- YEG-MCS vectors to be used as vectors and DNAs of HPV types 16 and 18 were conjugated using ligase (DAKARA, 2011a) and then transformed into dam (-) E. coli competent cells (TAKARA, 9129). Colonies formed after transformation were counted and cultured, respectively, and then plasmids were extracted and digested with enzymes to determine their size. The sized plasmid was transformed into yeast ( Saccharomyces cerevisiae ) and spread on SD (-ura) plates.
- yeast strain cells prepared above were inoculated in a flask equipped with a baffle in synthetic complete medium SD-ura (Clontech) without uracil, and shake-cultured at 30 ° C.
- YPDG medium was used to express HPV16 L1 and HPV18 L1 proteins from the GAL10 promoter.
- 1% yeast extract (DIFCO Laboratories, USA) and 2% peptone (DIFCO Laboratories, USA) were added to all medium and contained 1% glucose and 3% galactose. Plasmids were inoculated into 3 L of YPDG medium and incubated for 48 hours at 30 ° C.
- the cultured cells were obtained as pellets, and the obtained cell pellets were frozen at 70 ° C. All subsequent procedures were performed at 4 ° C.
- Cell pellets were dissolved and resuspended in 100 mL break buffer (20 mM sodium phosphate, pH 7.2, 100 mM NaCl, 1.7 mM EDTA, 0.01% Tween 80) and dissolved in a protease inhibitor cocktail (Roche, USA) was added.
- Cells were transferred to glass-beads (Sigma, USA) into a chamber of Bead-Beater (Biospec Products, USA), vortexed for 5 minutes, and the lysates at 10000 g for 10 minutes at 4 ° C. It was centrifuged several times and removed clearly.
- HPV L1 protein was recovered by adding ammonium sulfate (Sigma, USA) to the cleared cell lysate. To assess recovery efficiency, ammonium sulfate was added at 43% or 45% concentration, then stirred at 4 ° C. for 30 minutes and centrifuged at 12,000 g for 10 minutes to obtain protein pellets. The pellet precipitated with ammonium sulfate was resuspended in PBS + 0.01% Tween 80 buffer and further NaCl was added to bring the final NaCl concentration to at least 0.5 M. It was then incubated at 4 ° C. for at least 12 hours.
- ammonium sulfate Sigma, USA
- the solution incubated with the high concentration of NaCl was dialyzed with PBS + 0.01% Tween 80 buffer and then diluted with a solution containing 0.15 M NaCl and 0.01% Tween 80 in sodium phosphate pH 7.2 buffer to give a final protein concentration of 2-5 mg /. to ml.
- the solution was left at room temperature for 2 hours or longer to produce insoluble protein.
- the resulting insoluble protein was removed by centrifugation at 10000 g for 10 minutes.
- the supernatant was dialyzed with a binding buffer (PBS + 0.2 M NaCl pH 7.0, 0.01% Tween 80) after centrifugation of the low concentration NaCl incubated sample.
- Columns filled with heparin resin (5 ml or 20 ml) (GE healthcare, USA) were also equilibrated by flowing the binding buffer 5 times the resin volume.
- the dialysis solution was combined by passing through a heparin column and washed by pouring the binding buffer 5 times the resin volume.
- the elution method gave a linear concentration gradient to increase the NaCl concentration from 0.33 M to 0.66 M for 35 minutes to elute impurities, and then gave a linear concentration gradient from 0.66 M to 2 M to elute the L1 protein.
- the supernatant was dialyzed with binding buffer (PBS + 0.37 M NaCl pH 7.2, 0.01% Tween 80) after centrifugation of the low concentration NaCl incubated sample.
- binding buffer PBS + 0.37 M NaCl pH 7.2, 0.01% Tween 80
- An 8 cm x 4 cm Poly-Prep column (Bio-Rad Lab., USA) filled with P-11 cellulose phosphate resin (Whatman, UK) maintained the equilibrium by flowing the binding buffer five times the resin volume. .
- the dialysis solution was combined by passing through a P-11 column and washed by pouring the binding buffer 5 times the resin volume. After washing, 4-5 ml of the elution buffer containing 0.6 M, 0.7 M, 0.8 M and 1 M NaCl was flowed into the binding buffer to elute the L1 protein.
- 293TT cells such as p16SheLL (National Cancer Institute) and p18SheLL (National Cancer Institute), plasmids expressing L1 and L2 proteins of HPV types 16 and 18, as well as pYSEAP (National Cancer Institute), a plasmid containing reporter genes Co-transformation was performed using Lipofectamine 2000 (Invitrogen, USA) at the National Cancer Institute. Transformed 293TT cells were cultured for 72 hours and then disrupted using a lysis buffer (PBS + 0.5% Brij58, 0.2% Benzonase, 0.2% plasmid-safe ATP-dependent DNA). Cell debris of the crushed cells was removed by centrifugation at 12000 g for 10 minutes, and the supernatant was used for neutralizing antibody measurement.
- a lysis buffer PBS + 0.5% Brij58, 0.2% Benzonase, 0.2% plasmid-safe ATP-dependent DNA
- mice Six-week old female Balb / c mice were immunized subcutaneously three times every three weeks with 2 ⁇ g of L1 protein purified by heparin chromatography and cation-exchange chromatography, respectively. Primary immunization was performed using Freund's complete adjuvant (Sigma), and primary and secondary boosting were performed using Freund's incomplete adjuvant (Sigma). The control group was administered by diluting PBS in equal proportions to the complete fluid adjuvant and the complete fluid adjuvant. Serum was collected from the tail vein 10 days after the second boost for each group of mice, and neutralized antibodies were used for the measurement.
- 293TT cells were seeded in a 96 well plate at 3 ⁇ 10 4 cells / well and incubated in 37 ° C., 5% CO 2 incubator for 4 hours.
- Mouse sera immunized with L1 proteins of HPV types 16 and 18 were serially diluted from 1/100 to 10,000,000 and then diluted 1: 4 ratio with pseudoviruses of HPV types 16 and 18 prepared as above. The diluted mixture was reacted at 4 ° C. for 1 hour and then added to 293TT cells prepared in 96 well plates, followed by incubation at 37 ° C. and 5% CO 2 for 72 hours.
- SEAP SEAP in culture medium after 72 hours of incubation was determined using p-nitrophyl phosphate disodium salt hexahydrate (Sigma, USA) as a substrate.
- Neutralizing antibody titers in mouse serum were determined as half the OD values of wells to which pseudovirus only was applied.
- heparin chromatography contained a large amount of impurities in the case of the sample which was not incubated at low concentration of NaCl to remove insoluble impurities.
- the samples in which insoluble impurities were removed at low concentrations of NaCl significantly improved the purity of L1 protein in heparin chromatography (FIG. 5).
- the protein bound to the heparin column was eluted first with a gradient of 0.325 M to 0.66 M NaCl, and subsequently eluted with a concentration gradient from 0.66 M to 2 M NaCl.
- the HPV 16 L1 protein purified by the above two processes is magnetically modified into VLPs having a diameter (mean diameter 49 nm) of 35 nm to 64 nm, which is equivalent to the size of HPV VLPs.
- a diameter 49 nm of 35 nm to 64 nm, which is equivalent to the size of HPV VLPs.
- the proteins attached to the heparin column were first eluted with a gradient of 0.325 M to 0.66 M NaCl, followed by a second eluted gradient with a gradient of 0.66 M to 2 M NaCl. Most impurities were concentrated at concentrations of 0.325 M to 0.5 M NaCl. Eluted (FIG. 13) and HPV 18 L1 eluted at 1.2 M to 1.3 M NaCl concentration (FIG. 14). The results show that heparin chromatography, like HPV 16 L1, can effectively purify HPV 18 L1.
- HPV 18 L1 protein by cation-exchange chromatography was investigated. This result is the cation-exchange chromatography of Fig. 1C Method 2. As shown in FIG. 15, most impurities were removed by binding to the column, and HPV 18 L1 was eluted at 1 M NaCl concentration at 0.8 M when eluted with NaCl (FIG. 16). The results show that high purity L1 can be obtained by cation-exchange chromatography when insoluble protein is removed at low concentration of NaCl.
- the HPV 18 L1 protein purified by the above two processes are magnetically transformed into VLPs having a diameter (mean diameter 49 nm) of 35 nm to 64 nm, which is equivalent to the size of HPV VLPs.
- a diameter 49 nm of 35 nm to 64 nm, which is equivalent to the size of HPV VLPs.
- HPV 16 L1 and HPV 18 L1 proteins can be purified with high purity and high recovery rate without complicated steps and time-consuming methods such as Sukurose cushion or size-exclusion chromatography. .
- Neutralizing antibody titers were determined by immunizing mice with HPV type 16 and type 18 L1 proteins purified by the above method.
- L1 of HPV type 16 purified by heparin chromatography and cation-exchange chromatography showed neutralizing antibody titer to an average 1 / 18,000 dilution factor (FIG. 20).
- L1 purified by heparin chromatography showed an average of 1 / 5,000
- L1 purified by cation-exchange chromatography showed neutralizing antibody titers to an average dilution ratio of 1 / 170,000 (FIG. 21).
- the results show that the L1 proteins of HPV types 16 and 18 purified by the above method can induce neutralizing antibodies at high levels.
- Example 2 Production of very short lipopolysaccharide (LPS) CIA05 as a novel immune adjuvant
- the present inventors have already discovered a strain having a very short LPS ( E. coli EG0021) from E. coli living in the intestine of healthy human intestine. Deposited on the 2nd of February and assigned accession number KCCM 10374 (see Republic of Korea Patent No. 0456681; WO 2004/039413; Republic of Korea Patent No. 0740237; WO 2006/121232). LPS purification from the strain is Korean Patent Registration No. 0456681; WO 2004/039413; Korean Patent Registration No. 0740237; And the method disclosed in WO 2006/121232.
- the molecular weight of the purified LPS was measured by MALDI-MASS (Shimadz, Axima-LNR V 2.3.5 (Mode Liner, Power: 106)), it was confirmed that the molecular weight of about 3,500 Da.
- Purified LPS is Korean Patent Registration No. 0456681; WO 2004/039413; Korean Patent Registration No. 0740237; And detoxification according to the protocol disclosed according to the method disclosed in WO 2006/121232. Briefly, mix 2 N NaOH in 1: 1 volume with 3 mg / ml of the purified LPS, shake once every 10 minutes at 60 ° C., deacylated for 140 minutes, and about 1/5 of the initial 0.2 N NaOH volume. 1 N acetic acid was added and titrated to pH 7.0. Ethanol precipitation after pH titration gave a non-toxic lipopolysaccharide (CIA05).
- PBMC Peripheral Blood Mononuclear Cells
- Each prepared dish was treated with the following conditions: 1) negative control group: 100 ⁇ l of balanced salt solution (BSS); 2) 10 ⁇ g / 100 ⁇ l of deacylated non-toxic LOS (CIA05); 3) 10 ⁇ g / 100 ⁇ l of MPL ( E. coli F583 MPL).
- BSS balanced salt solution
- CIA05 10 ⁇ g / 100 ⁇ l of deacylated non-toxic LOS
- MPL E. coli F583 MPL
- TNF- ⁇ an inflammatory protein secreted from THP-1 (Acute monocytic leukemia) using the ELISA kit (R & D system, DY210). Each was measured. As a result, as shown in Figure 22, it was confirmed that about 1/3 of the toxicity is less than the MPL used as a conventional cervical cancer vaccine adjuvant.
- Immune responses were induced in mice using protein antigens purified through the above experiments and CIA05, a novel immune adjuvant.
- Six-week-old male Balb / c mice (SLC, Japan) were used, and five mice were randomly assigned to each experimental group.
- 2 ⁇ g of HPV16 L1 VLP (FIGS. 12A-12C)
- 1 ⁇ g or 4 ⁇ g (CIA05 alone, Alum (aluminum hydroxide; Brenntag, Germany) alone or a mixture of both)
- Each type of 0.5 ⁇ g or 2 ⁇ g) (FIGS. 13A-15) was immunized by intramuscular injection three times at two week intervals. Control mice received PBS.
- Cervarix TM and Gardasil TM both commercially available products, were administered to mice at a 1/10 dose of human standard. Sera of the mice were harvested 5 weeks after the third inoculation, and anti-L1 VLP IgG titers were measured by endpoint ELISA.
- 96-well ELISA microplates (Nalge Nunc International) were diluted in 100 ⁇ l of the coating buffer (50 mM carbonate, pH 9.6, 4 ° C.) by diluting the HPV type 16 or 18 VLP L1 antigen prepared in the above example to a concentration of 0.5 ⁇ g / ml. , USA) and then coated at 4 ° C overnight. The following day, each well was washed three times using a wash buffer (PBS dissolved in 0.05% Tween20), and 300 ⁇ l of each blocking buffer (PBS dissolved in 1% BSA) was added at each well at 37 ° C. Blocked for one hour.
- the coating buffer 50 mM carbonate, pH 9.6, 4 ° C.
- TMB tetramethylbenzidine, BD Bioscience, 55555214
- 100 ⁇ l of 1N H 2 SO 4 was added immediately to complete the color reaction.
- the color development degree (concentration) of each well was measured at the wavelength of. Endpoint titers were defined as the highest serum dilution resulting in two-fold absorbance of non-immune serum with a cut-off value of 0.1, expressed as mean ⁇ SD.
- HPV16 / 18 L1 VLP specific total IgG titer was much higher than Alum alone when CIA05 adjuvant and Alum were administered in combination, and immunized with conventional Cervarix TM and Gardasil TM . Better than one group.
- Spleens were extracted as sterilely as possible from mice immunized in the above manner and washed with PBS. Ten holes were punctured in the spleen using a 5 ml syringe in culture (50 ⁇ M ⁇ -mercaptoethanol, 1 M HEPES buffer, 10% FBS, 1 ⁇ antibiotic added RPMI1640). The splenocytes were separated by sucking the culture medium in a syringe and repeatedly blowing several times. The separated splenocytes were collected and centrifuged at 1500 rpm and 4 ° C for 10 minutes with the culture medium.
- the culture was removed and resuspended using RPMI1640 medium containing 100 ⁇ g / ml streptomycin and 50 mM ⁇ -mercaptoethanol in 10% FBS.
- Spleen cells were then dispensed into each well of a 96-well plate and HPV16 L1 VLPs were added at a concentration of 15 ⁇ g / ml and then incubated for 72 hours at 37 ° C. for 48 hours.
- the concentration of interferon- ⁇ secreted from mouse splenocytes was measured by ELISA (BD OptEIA mouse ELISA kit).
- the vaccine composition of the present invention in FIGS. 26, 27, 28 and 29 comprises L1 VLPs, aluminum hydroxide and CIA05 of HPV types 16 and 18, which replaced CIA05 instead of MPL in Cervarix of GSK. can see. That is, it can be seen that CIA05 used in the present invention is far superior to MPL in terms of toxicity as well as immunostimulating ability against HPV.
- the experimental results of the HPV16 L1 VLP and HPV18 L1 VLP, the experimental group mixed with the adjuvant CIA05 developed by the present inventors can be seen to show a superior immune effect than the experimental group immunized with the conventional cervical cancer vaccine.
- the present invention can be said to be an original and advanced invention that can solve the problem through the addition of an adjuvant.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (16)
- (a) (ⅰ) 인간 파필로마 바이러스(HPV) 타입 16의 L1 바이러스-유사 입자(VLP), HPV 타입 18의 L1 VLP 또는 이의 조합; 및 (ⅱ) 탈아실화 비독성 LOS(Lipooligosaccharide); 그리고,(b) 약제학적으로 허용되는 담체를 포함하는 인간 자궁경부암 백신 약제학적 조성물.
- 제 1 항에 있어서, 상기 HPV 타입 16 또는 18의 L1 VLP는 (i) HPV 타입 16 또는 18의 L1-코딩 뉴클레오타이드 서열을 포함하는 이스트(yeast)를 배양하는 단계; (ⅱ) 상기 배양된 이스트를 용해(lysis)하는 단계; (ⅲ) 상기 이스트 용해물(lysate)에 대하여 암모늄 설페이트 침전을 실시하여 불순물을 제거하는 단계; 및 (ⅳ) 상기 불순물이 제거된 결과물에 대하여 헤파린 크로마토그래피(heparin chromatography) 또는 양이온 교환 크로마토그래피(cation-exchange chromatography)를 실시하는 단계를 포함하는 정제과정을 통하여 수득한 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 상기 비독성 LOS는 LPS에 알카리 처리하여 지질 A의 탈아실화 되어 비독성화 된 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 상기 비독성 LOS는 1,500-10,000 Da의 분자량을 가지는 것을 특징으로 하는 조성물.
- 제 4 항에 있어서, 상기 비독성 LOS는 2,000-4,000 Da의 분자량을 가지는 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 상기 비독성 LOS는 E. coli 유래된 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 상기 약제학적 조성물은 면역보조제를 추가적으로 포함하며 상기 면역보조제는 Mg, Ca, Sr, Ba 및 Ra으로 구성된 군으로부터 선택되는 제2족 원소, Ti, Zr, Hf 및 Rf로 구성된 군으로부터 선택되는 제4족 원소 또는 알루미늄의 염 또는 그의 수화물인 것을 특징으로 하는 조성물.
- 상기 제 1 항 내지 제 7 항 중 어느 한 항의 약제학적 조성물을 인간에게 투여하는 단계를 포함하는 인간 자궁경부암 예방 방법.
- 다음의 단계를 포함하는 인간 파필로마 바이러스(HPV) L1 바이러스-유사 입자(VLP)의 제조방법:(i) HPV L1-코딩 뉴클레오타이드 서열을 포함하는 이스트(yeast)를 배양하는 단계;(ⅱ) 상기 배양된 이스트를 용해(lysis)하는 단계;(ⅲ) 상기 이스트 용해물(lysate)에 대하여 암모늄 설페이트 침전을 실시하여 불순물을 제거하는 단계; 및(ⅳ) 상기 불순물이 제거된 결과물에 대하여 헤파린 크로마토그래피(heparin chromatography) 또는 양이온 교환 크로마토그래피(cation-exchange chromatography)를 실시하는 단계.
- 제 9 항에 있어서, 상기 HPV는 HPV 타입 16 또는 HPV 타입 18인 것을 특징으로 하는 방법.
- 제 9 항에 있어서, 상기 단계 (ⅲ) 및 (ⅳ) 사이에 단계 (ⅲ-2) 암모늄 설페이트 침전을 실시하여 불순물을 제거된 결과물을 0.001-0.3 M의 NaCl로 처리하여 추가적으로 불순물을 제거하는 단계를 추가적으로 포함하는 것을 특징으로 하는 방법.
- 제 9 항에 있어서, 상기 양이온 교환 크로마토그래피는 포스페이트기를 가지는 양이온교환제를 이용하여 실시하는 것을 특징으로 하는 방법.
- 서열목록 제1서열의 뉴클레오타이드 서열을 포함하는 인간 파필로마 바이러스(HPV) 타입 16의 L1 바이러스-유사 입자(VLP)의 핵산서열.
- 서열목록 제3서열의 뉴클레오타이드 서열을 포함하는 인간 파필로마 바이러스(HPV) 타입 18의 L1 바이러스-유사 입자(VLP)의 핵산서열.
- 상기 제 13 항의 인간 파필로마 바이러스(HPV) 타입 16의 L1 바이러스-유사 입자(VLP)의 핵산서열로 형질전환된 사카로마이세스 세레비시애(기탁번호: KCCM11036P).
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL09846240T PL2444103T3 (pl) | 2009-06-19 | 2009-10-20 | Szczepionka przeciwko rakowi szyjki macicy |
JP2012515957A JP5758385B2 (ja) | 2009-06-19 | 2009-10-20 | 子宮頸がんワクチン |
US13/379,212 US9566323B2 (en) | 2009-06-19 | 2009-10-20 | Vaccine for cervical cancer |
AU2009348078A AU2009348078B2 (en) | 2009-06-19 | 2009-10-20 | Vaccine for cervical cancer |
BRPI0924981-8A BRPI0924981B1 (pt) | 2009-06-19 | 2009-10-20 | Composição de vacina para câncer cervical |
MX2011013566A MX2011013566A (es) | 2009-06-19 | 2009-10-20 | Vacunas para cancer cervical. |
CN200980111082.4A CN102215861B (zh) | 2009-06-19 | 2009-10-20 | 宫颈癌疫苗 |
EP09846240.1A EP2444103B1 (en) | 2009-06-19 | 2009-10-20 | Vaccine for cervical cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20090055179 | 2009-06-19 | ||
KR10-2009-0055179 | 2009-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010147268A1 true WO2010147268A1 (ko) | 2010-12-23 |
Family
ID=43356558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/006062 WO2010147268A1 (ko) | 2009-06-19 | 2009-10-20 | 자궁경부암 백신 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9566323B2 (ko) |
EP (1) | EP2444103B1 (ko) |
JP (1) | JP5758385B2 (ko) |
KR (3) | KR101181907B1 (ko) |
CN (2) | CN102215861B (ko) |
AU (1) | AU2009348078B2 (ko) |
BR (1) | BRPI0924981B1 (ko) |
MX (1) | MX2011013566A (ko) |
PL (1) | PL2444103T3 (ko) |
TR (1) | TR201802597T4 (ko) |
WO (1) | WO2010147268A1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013151382A1 (ko) * | 2012-04-06 | 2013-10-10 | 아이진 주식회사 | 두 가지 항암물질을 동시에 제공하는 대장균 균주 |
EP2722389A2 (en) * | 2011-06-15 | 2014-04-23 | Chung-Ang University Industry-Academy Cooperation Foundation | Method for enhancing the production yield of human papillomavirus l1 protein |
JP2015524817A (ja) * | 2012-07-30 | 2015-08-27 | キム、ホン‐ジンKim, Hong‐Jin | ヒトパピローマウイルスのウイルス様粒子の高効率精製方法 |
CN106390109A (zh) * | 2010-12-18 | 2017-02-15 | 艾金株式会社 | 诱导改善的免疫反应的疫苗 |
US9771397B2 (en) | 2011-12-01 | 2017-09-26 | University Of Cape Town | HPV chimaeric particle |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7999085B2 (en) * | 2007-01-09 | 2011-08-16 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
WO2014046410A1 (ko) * | 2012-09-20 | 2014-03-27 | 중앙대학교 산학협력단 | 노다바이러스의 바이러스 유사입자의 생산방법, 이를 발현하는 효모 세포주 및 이를 포함하는 백신 조성물 |
KR20140060053A (ko) * | 2012-11-09 | 2014-05-19 | 아이진 주식회사 | 인플루엔자 백신용 면역증강제 |
CA2958222A1 (en) * | 2014-09-11 | 2016-03-17 | Cadila Healthcare Limited | Superior human papilloma virus antigens with superior immunological properties and vaccine containing it |
US10799574B2 (en) | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
MY195018A (en) | 2014-10-24 | 2023-01-03 | Hpvvax Llc | Cancer and skin lesion treatment |
EA201790944A1 (ru) * | 2014-12-26 | 2017-11-30 | Айджин, Инк. | Способ получения вирусоподобных частиц папилломавируса человека |
US10918709B2 (en) | 2016-10-31 | 2021-02-16 | Eyegene Inc. | Immune modulator and vaccine composition containing the same |
CN110461355B (zh) * | 2016-10-31 | 2023-06-09 | 艾金株式会社 | 包含免疫调控剂和阳离子脂质体的免疫增强的组合物及其用途 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
US5618536A (en) | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
US5888516A (en) | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
US6613557B1 (en) | 1991-07-19 | 2003-09-02 | The University Of Queensland | Papillomavirus HPV16 L1 polynucleotide |
EP1410805A1 (en) * | 1999-09-07 | 2004-04-21 | GlaxoSmithKline Biologicals S.A. | Vaccine against HPV |
WO2004039413A1 (en) | 2002-05-22 | 2004-05-13 | Eyegene Inc | Immune stimulating and controlling composition comprising bacterial chromosomal dna fragments and non-toxic lipopolysaccharides |
US20060251676A1 (en) * | 2002-12-20 | 2006-11-09 | Gary Dubin | Hpv-16 and-18 l1 vlp vaccine |
WO2006121232A1 (en) | 2005-05-10 | 2006-11-16 | Eyegene Inc. | Adjuvant comprising oligonucleotide and non toxic lps |
US7250170B2 (en) | 2003-09-29 | 2007-07-31 | Merck & Co., Inc. | Optimized expression of HPV 45 L1 in yeast |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA96005662A (es) * | 1994-05-16 | 2004-08-19 | Merck & Co Inc | Vacunas de papilomavirus. |
AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
US6685949B1 (en) * | 1998-01-13 | 2004-02-03 | The United States Of America As Represented By The Department Of Health & Human Services | Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans |
GB9907553D0 (en) * | 1999-04-01 | 1999-05-26 | Cantab Pharma Res | Purification of biological preparations |
KR100423480B1 (ko) * | 2001-11-20 | 2004-03-18 | 삼성전자주식회사 | 복수의 토너농도센서를 가지는 프린터 및 그의토너공급제어방법 |
SI1572233T1 (sl) * | 2002-12-20 | 2011-07-29 | Glaxosmithkline Biolog Sa | Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68 |
US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
GB0323968D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
PL1758609T3 (pl) * | 2004-06-16 | 2013-02-28 | Glaxosmithkline Biologicals Sa | Szczepionka przeciw HPV16 i HPV18 oraz co najmniej jednemu HPV innego typu wybranemu spośród HPV 31, 45 lub 52 |
CA2606092A1 (en) * | 2005-04-26 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
MX2007013475A (es) * | 2005-04-26 | 2008-04-02 | Glaxosmithkline Biolog Sa | Vacuna. |
EA200702254A1 (ru) * | 2005-05-19 | 2008-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант |
EP1885394A4 (en) * | 2005-06-01 | 2009-10-21 | Dow Global Technologies Inc | PRODUCTION OF MULTIVALENT PARTICLES LIKE VIRUSES |
TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
CN101394857A (zh) * | 2006-02-01 | 2009-03-25 | 爱吉恩公司 | 含有寡聚核苷酸和无毒lps的用于治疗癌症的组合物 |
-
2009
- 2009-10-20 WO PCT/KR2009/006062 patent/WO2010147268A1/ko active Application Filing
- 2009-10-20 AU AU2009348078A patent/AU2009348078B2/en active Active
- 2009-10-20 BR BRPI0924981-8A patent/BRPI0924981B1/pt active IP Right Grant
- 2009-10-20 CN CN200980111082.4A patent/CN102215861B/zh active Active
- 2009-10-20 JP JP2012515957A patent/JP5758385B2/ja active Active
- 2009-10-20 MX MX2011013566A patent/MX2011013566A/es active IP Right Grant
- 2009-10-20 KR KR1020090099982A patent/KR101181907B1/ko active IP Right Grant
- 2009-10-20 EP EP09846240.1A patent/EP2444103B1/en active Active
- 2009-10-20 US US13/379,212 patent/US9566323B2/en active Active
- 2009-10-20 CN CN201410444512.7A patent/CN104288763B/zh active Active
- 2009-10-20 PL PL09846240T patent/PL2444103T3/pl unknown
- 2009-10-20 TR TR2018/02597T patent/TR201802597T4/tr unknown
-
2012
- 2012-07-13 KR KR1020120076878A patent/KR101345205B1/ko active IP Right Grant
-
2013
- 2013-07-08 KR KR1020130079935A patent/KR101595779B1/ko active IP Right Grant
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613557B1 (en) | 1991-07-19 | 2003-09-02 | The University Of Queensland | Papillomavirus HPV16 L1 polynucleotide |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
US5618536A (en) | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
US5871998A (en) | 1992-09-03 | 1999-02-16 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
US5888516A (en) | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
EP1410805A1 (en) * | 1999-09-07 | 2004-04-21 | GlaxoSmithKline Biologicals S.A. | Vaccine against HPV |
WO2004039413A1 (en) | 2002-05-22 | 2004-05-13 | Eyegene Inc | Immune stimulating and controlling composition comprising bacterial chromosomal dna fragments and non-toxic lipopolysaccharides |
KR100456681B1 (ko) | 2002-05-22 | 2004-11-10 | 주식회사 대웅 | 박테리아의 염색체 dna 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물 |
US20060251676A1 (en) * | 2002-12-20 | 2006-11-09 | Gary Dubin | Hpv-16 and-18 l1 vlp vaccine |
US7250170B2 (en) | 2003-09-29 | 2007-07-31 | Merck & Co., Inc. | Optimized expression of HPV 45 L1 in yeast |
WO2006121232A1 (en) | 2005-05-10 | 2006-11-16 | Eyegene Inc. | Adjuvant comprising oligonucleotide and non toxic lps |
KR100740237B1 (ko) | 2005-05-10 | 2007-07-18 | 아이진 주식회사 | 올리고뉴클레오타이드 및 비독성 다당체를 포함하는면역보조제 |
Non-Patent Citations (24)
Title |
---|
ALBER, T.; KAWASAKI, G., J. MOL. & APPL. GENET., vol. 1, 1982, pages 419 - 434 |
CLIN IMMUNOL., vol. 100, no. 2, August 2001 (2001-08-01), pages 157 - 63 |
EMBO J., vol. 6, 1982, pages 675 - 680 |
GAO JJ.: "Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism", J IMMUNOL, vol. 166, no. 11, 2001, pages 6855 - 60 |
GENNARO: "Remington's Pharmaceutical Sciences(19th ed.,", 1995 |
GLICK, J. L.: "The specificity of inhibition of tumor cell viability by DNA", CANCER RES., vol. 27, 1967, pages 2338 |
HAUSEN, BIOCHEMICA. BIOPHYSICA. ACTA., vol. 1288, 1996, pages 55 - 78 |
J CLIN IMMUNOL., vol. 6, no. 4, July 1986 (1986-07-01), pages 292 - 8 |
JOHNSON, M.; DAVIES, R. W., MOL, AND CELL. BIOL., vol. 4, 1984, pages 1440 - 1448 |
K. A. AIRES ET AL., APPL. ENVIRON. 368 MICROBIOL., vol. 72, 2006, pages 745 - 752 |
KATZ SS: "Deacylation of lipopolysaccharide in whole Escherichia coli during destruction by cellular and extracellular components of a rabbit peritoneal inflammatory exudate", J BIOL CHEM., vol. 274, no. 51, 17 December 1999 (1999-12-17), pages 36579 - 84 |
KRIEG AM: "Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides", CURR. ONCOL. REP., vol. 6, no. 2, March 2004 (2004-03-01), pages 88 - 95 |
LEBMAN DA ET AL.: "Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures", J EXP MED., vol. 168, no. 3, 1 September 1988 (1988-09-01), pages 853 - 62 |
M.P. MCCARTHY; W.I. WHITE; F. PALMER-HILL; S. KOENIG; J.A. SUZICH, J VIROL, vol. 72, 1998, pages 32 - 41 |
MCCLUSKIE MJ ET AL.: "CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice", J IMMUNOL. NOVL, vol. 161, no. 9, 1998, pages 4463 - 6 |
MOL IMMUNOL., vol. 35, no. 18, December 1998 (1998-12-01), pages 1161 - 70 |
R. KIRNBAUER ET AL., J VIROL, vol. 67, 1993, pages 6929 - 6936 |
RENGARAJAN J ET AL.: "Transcriptional regulation of Thl/Th2 polarization", IMMUNOL TODAY., vol. 21, no. 10, October 2000 (2000-10-01), pages 479 - 83 |
RUSSELL, D. ET AL., J. BIOL. CHEM., vol. 258, 1983, pages 2674 - 2682 |
S. N. KIM, J. VIROL. METHODS, vol. 139, 2007, pages 24 - 30 |
S.N. KIM ET AL., J. VIROL. METHODS, vol. 139, 2007, pages 24 - 30 |
See also references of EP2444103A4 |
YAMAMOTO S.: "Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity", J. IMMUNOL., vol. 148, 1992, pages 4072 |
ZUR HAUSEN H, MOL. CARCINOGENESIS, vol. 8, 1988, pages 147 - 150 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106390109A (zh) * | 2010-12-18 | 2017-02-15 | 艾金株式会社 | 诱导改善的免疫反应的疫苗 |
EP2722389A2 (en) * | 2011-06-15 | 2014-04-23 | Chung-Ang University Industry-Academy Cooperation Foundation | Method for enhancing the production yield of human papillomavirus l1 protein |
JP2014519339A (ja) * | 2011-06-15 | 2014-08-14 | チュンアン ユニバーシティー インダストリー−アカデミー コオペレーション ファウンデーション | ヒトパピローマウイルスl1タンパク質の生産収率を向上させる方法 |
EP2722389A4 (en) * | 2011-06-15 | 2015-01-21 | Univ Chung Ang Ind | METHOD FOR INCREASING PRODUCTION YIELD OF L1 PROTEIN OF HUMAN PAPILLOMAVIRUS |
US9771397B2 (en) | 2011-12-01 | 2017-09-26 | University Of Cape Town | HPV chimaeric particle |
WO2013151382A1 (ko) * | 2012-04-06 | 2013-10-10 | 아이진 주식회사 | 두 가지 항암물질을 동시에 제공하는 대장균 균주 |
KR101452830B1 (ko) | 2012-04-06 | 2014-10-21 | 아이진 주식회사 | 두 가지 항암물질을 동시에 제공하는 대장균 균주 |
JP2015524817A (ja) * | 2012-07-30 | 2015-08-27 | キム、ホン‐ジンKim, Hong‐Jin | ヒトパピローマウイルスのウイルス様粒子の高効率精製方法 |
US9994618B2 (en) | 2012-07-30 | 2018-06-12 | Hong-Jin Kim | High efficiency method for purifying human papillomavirus virus-like particles |
Also Published As
Publication number | Publication date |
---|---|
CN104288763A (zh) | 2015-01-21 |
CN102215861B (zh) | 2014-10-08 |
PL2444103T3 (pl) | 2018-05-30 |
MX2011013566A (es) | 2012-06-28 |
BRPI0924981B1 (pt) | 2022-02-08 |
AU2009348078B2 (en) | 2013-03-14 |
BRPI0924981A2 (pt) | 2016-03-15 |
KR20100136889A (ko) | 2010-12-29 |
KR20120083263A (ko) | 2012-07-25 |
JP2012530488A (ja) | 2012-12-06 |
TR201802597T4 (tr) | 2018-03-21 |
KR101345205B1 (ko) | 2013-12-27 |
CN104288763B (zh) | 2018-03-06 |
EP2444103A4 (en) | 2013-12-18 |
CN102215861A (zh) | 2011-10-12 |
KR101181907B1 (ko) | 2012-09-11 |
US9566323B2 (en) | 2017-02-14 |
KR101595779B1 (ko) | 2016-02-19 |
JP5758385B2 (ja) | 2015-08-05 |
EP2444103B1 (en) | 2017-12-20 |
US20120100169A1 (en) | 2012-04-26 |
AU2009348078A1 (en) | 2011-12-15 |
EP2444103A1 (en) | 2012-04-25 |
KR20130083426A (ko) | 2013-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010147268A1 (ko) | 자궁경부암 백신 | |
US6066324A (en) | Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles | |
Franconi et al. | Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection | |
WO2019209079A1 (en) | Nucleic acid molecules inserted expression regulation sequences, expression vector comprising nucleic acid moleclues and pharmaceutical use thereof | |
WO2009088256A9 (ko) | 배큘로바이러스-기반 백신 | |
JP2001527091A (ja) | ワクチン | |
WO2010079991A2 (ko) | 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균 | |
WO2019151760A1 (ko) | 신규 다가 hpv 백신 조성물 | |
WO2020091529A1 (ko) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 | |
WO2020005028A1 (ko) | 중증 열성 혈소판 감소 증후군(sfts) 바이러스 감염 질환 예방 또는 치료용 백신 조성물 | |
KR20040034511A (ko) | 인간 파필로마바이러스에 대한 백신용 벡터 및 그에 의해형질전환된 미생물 | |
KR101178056B1 (ko) | 자궁경부암 백신 | |
WO2014021604A1 (ko) | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 | |
WO2020246750A2 (ko) | 안정화된 핵산 면역증강제를 함유하는 약학 조성물 | |
WO2019212312A1 (ko) | 키메라 지카바이러스 백신 | |
WO2019066437A1 (ko) | 가용성 변형 호흡기 융합세포 바이러스 (rsv) f 단백질 항원 | |
WO2022050520A1 (ko) | 코로나바이러스 유래 수용체 결합 도메인 및 뉴클레오캡시드 단백질을 포함하는 융합단백질 및 이의 용도 | |
WO2024014894A1 (ko) | 항원 단백질 또는 상기 단백질을 암호화하는 유전자를 포함하는 세포외소포체 및 그의 용도 | |
WO2023075421A1 (ko) | 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물 | |
WO2022216025A1 (ko) | Sars-cov-2 항원을 발현하는 재조합 마이코박테리움 균주 및 이를 포함하는 백신 조성물 | |
WO2022211373A1 (ko) | 침팬지 아데노바이러스 혈청형 6의 돌기 유전자로 치환된 재조합 키메릭 아데노바이러스 벡터 및 그 응용 | |
WO2012053856A2 (ko) | 호흡기 신시치아 바이러스 백신 조성물 및 그의 제조방법 | |
WO2021241928A1 (ko) | 사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질, 그 단백질의 용도 | |
WO2023101381A1 (ko) | 구제역 바이러스 유사 입자를 생산하기 위한 백신 플랫폼 | |
WO2022216028A1 (ko) | 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방용 중화능 개량 백신 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980111082.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09846240 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009846240 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009348078 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8912/CHENP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012515957 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/013566 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2009348078 Country of ref document: AU Date of ref document: 20091020 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011003206 Country of ref document: CL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13379212 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0924981 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI0924981 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111216 |